Basit öğe kaydını göster

dc.contributor.authorKim, Dennis
dc.contributor.authorGruenwald, Viktor
dc.contributor.authorOu, Yen-chuan
dc.contributor.authorPanneerselvam, Ashok
dc.contributor.authorAnak, Oezlem
dc.contributor.authorvan den Eertwegh, Alfonsus J. M.
dc.contributor.authorKarakiewicz, Pierre
dc.contributor.authorBavbek, Sevil
dc.contributor.authorRha, Sun Young
dc.contributor.authorBracarda, Sergio
dc.contributor.authorBahl, Amit
dc.date.accessioned2021-03-03T14:36:12Z
dc.date.available2021-03-03T14:36:12Z
dc.date.issued2013
dc.identifier.citationvan den Eertwegh A. J. M. , Karakiewicz P., Bavbek S., Rha S. Y. , Bracarda S., Bahl A., Ou Y., Kim D., Panneerselvam A., Anak O., et al., "Safety of Everolimus by Treatment Duration in Patients With Advanced Renal Cell Cancer in an Expanded Access Program", UROLOGY, cilt.81, sa.1, ss.143-149, 2013
dc.identifier.issn0090-4295
dc.identifier.othervv_1032021
dc.identifier.otherav_3a79c5f0-9249-4839-b554-5dce1b17a751
dc.identifier.urihttp://hdl.handle.net/20.500.12627/43271
dc.identifier.urihttps://doi.org/10.1016/j.urology.2012.09.019
dc.description.abstractOBJECTIVE To retrospectively analyze the effects of treatment duration on outcomes of everolimus treatment of patients in the RAD001 Expanded-Access Clinical Trial in RCC (REACT) program.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectNefroloji
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectÜROLOJİ VE NEFROLOJİ
dc.titleSafety of Everolimus by Treatment Duration in Patients With Advanced Renal Cell Cancer in an Expanded Access Program
dc.typeMakale
dc.relation.journalUROLOGY
dc.contributor.departmentVrije Universiteit Amsterdam , ,
dc.identifier.volume81
dc.identifier.issue1
dc.identifier.startpage143
dc.identifier.endpage149
dc.contributor.firstauthorID207907


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster